| 4.92 0.06 (1.23%) | 07-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.28 |
1-year : | 7.33 |
| Resists | First : | 5.38 |
Second : | 6.28 |
| Pivot price | 3.39 |
|||
| Supports | First : | 3.65 |
Second : | 2.58 |
| MAs | MA(5) : | 4.02 |
MA(20) : | 3.26 |
| MA(100) : | 3.37 |
MA(250) : | 4.63  |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 89.8 |
D(3) : | 84.1 |
| RSI | RSI(14): 72.9 |
|||
| 52-week | High : | 12.5 | Low : | 2.06 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ICU ] has closed It is unclear right now based on current values. 109.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.38 - 5.4 | 5.4 - 5.42 |
| Low: | 4.51 - 4.52 | 4.52 - 4.54 |
| Close: | 4.89 - 4.92 | 4.92 - 4.95 |
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Thu, 02 Jul 2026
SeaStar Medical (ICU) director awarded 4,000 RSUs, holdings now 16,200 shares - Stock Titan
Thu, 02 Jul 2026
SeaStar Medical (ICU) CEO receives 10,288 restricted stock units in equity grant - Stock Titan
Thu, 02 Jul 2026
Form 4 SeaStar Medical Holding Corp For: 2 July By Investing.com - Investing.com Canada
Thu, 02 Jul 2026
SeaStar Medical (ICU) grants CMO 7,202 restricted stock units - Stock Titan
Thu, 02 Jul 2026
4,000-share RSU grant to SeaStar Medical (ICU) director disclosed - Stock Titan
Thu, 02 Jul 2026
SeaStar Medical (ICU) director granted 4,000 restricted stock units - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 11.9 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 129 (K) |
| Shares Short P.Month | 155 (K) |
| EPS | -2.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.83 |
| Profit Margin | 0 % |
| Operating Margin | -727.9 % |
| Return on Assets (ttm) | -79.3 % |
| Return on Equity (ttm) | -302.1 % |
| Qtrly Rev. Growth | 68.9 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -2.07 |
| PEG Ratio | 0 |
| Price to Book value | 2.68 |
| Price to Sales | 13.66 |
| Price to Cash Flow | -1.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|